The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.
Reads0
Chats0
TLDR
In this paper, the application of nanobodies as a new class of recombinant antibodies in COVID-19 treatment was described, where the VHH's high affinity attachment to the receptor-binding domain (RBD) allowed the neutralization of SARS-CoV-2.Abstract:
The severe acute respiratory syndrome (SARS-CoV-2), a newly emerging of coronavirus, continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that disrupt the interaction of RBD and ACE2 has been under the spotlight as a way of developing the COVID-19 treatment. Some animals, such as llamas, manufacture heavy-chain antibodies that have a single variable domain (VHH) instead of two variable domains (VH/VL) as opposed to typical antibodies. Nanobodies are antigen-specific, single-domain, changeable segments of camelid heavy chain-only antibodies that are recombinantly produced. These types of antibodies exhibit a wide range of strong physical and chemical properties, like high solubility, and stability. The VHH's high-affinity attachment to the receptor-binding domain (RBD) allowed the neutralization of SARS-CoV-2. To tackle COVID-19, some nanobodies are being developed against SARS-CoV-2, some of which have been recently included in clinical trials. Nanobody therapy may be useful in managing the COVID-19 pandemic as a potent and low-cost treatment. This paper describes the application of nanobodies as a new class of recombinant antibodies in COVID-19 treatment.read more
Citations
More filters
Journal ArticleDOI
A Class of Shark‐Derived Single‐Domain Antibodies can Broadly Neutralize SARS‐Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape
Bo Feng,Zhilong Chen,Jing Sun,Tingting Xu,Qian Wang,Haisu Yi,Xuefeng Niu,Jiabin Zhu,Mengzhu Fan,Rui-tian Hou,Ying Shao,Sihui Huang,Cuiyun Li,Peiyu Hu,Pingqian Zheng,Ping He,Jia Luo,Qihong Yan,Xiaoli Xiong,Jinsong Liu,Jincun Zhao,Ling Chen +21 more
TL;DR: It is found that the S375F mutation on Omicron RBD disrupts the structure of β‐strand, thus impair the binding with 20G6, and demonstrates that shark‐derived vnarbodies offer a prophylactic and therapeutic option against most SARS‐CoV‐2 variants and provide insights into antibody evasion by the OmicRON variant.
Journal ArticleDOI
Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development.
Bingxuan Li,Xiaohong Qin,L. Mi +2 more
TL;DR: Recent studies on the nanobODY structure, screening and their applications in protein structure analysis and nanobody drugs, especially on non-injectable nanob Cody and bispecific nanobodies development are reviewed.
Journal ArticleDOI
Nanobodies: Robust Miniprotein Binders in Biomedicine.
TL;DR: In this article , the structural features of variable domains of heavy chain-only antibodies (VHHs) are discussed and a review of recent advances in using Nbs as a modular scaffold to facilitate the engineering of multivalent polymers for cutting-edge applications is presented.
Journal ArticleDOI
The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics
TL;DR: In this article , the authors discuss the challenges and limitations of conventional COVID-19 diagnostics and therapeutics, and the advantages of Nbs against SARS-CoV-2 as well as their diagnostic and therapeutic potential.
Journal ArticleDOI
Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update
TL;DR: In this article , the authors discuss about the single-domain antibodies (sdAbs), also called nanobodies, their structure, and their types against the infections of dreadful SARS-CoV-2 virus.
References
More filters
Journal ArticleDOI
A Novel Coronavirus from Patients with Pneumonia in China, 2019.
Na Zhu,Dingyu Zhang,Wenling Wang,Xingwang Li,Bo Yang,Jingdong Song,Xiang Zhao,Baoying Huang,Weifeng Shi,Roujian Lu,Peihua Niu,Faxian Zhan,Xuejun Ma,Dayan Wang,Wenbo Xu,Wenbo Xu,Guizhen Wu,George F. Gao,Wenjie Tan +18 more
TL;DR: Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily, which is the seventh member of the family of coronaviruses that infect humans.
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.
Qun Li,Xuhua Guan,Peng Wu,Xiaoye Wang,Lei Zhou,Yeqing Tong,Ruiqi Ren,Kathy Leung,Eric H. Y. Lau,Jessica Y. Wong,Xuesen Xing,Nijuan Xiang,Yang Wu,Chao Li,Chen Qi,Dan Li,Tian Liu,Jing Zhao,Man Liu,Wenxiao Tu,Chuding Chen,Lianmei Jin,Rui Yang,Qi Wang,Suhua Zhou,Rui Wang,Hui Liu,Yingbo Luo,Yuan Liu,Ge Shao,Huan Li,Zhongfa Tao,Yang Yang,Yang Yang,Zhiqiang Deng,Boxi Liu,Zhitao Ma,Yanping Zhang,Guoqing Shi,Tommy Tsan-Yuk Lam,Joseph T. Wu,George F. Gao,George F. Gao,Benjamin J. Cowling,Bo Yang,Gabriel M. Leung,Zijian Feng +46 more
TL;DR: There is evidence that human-to-human transmission has occurred among close contacts since the middle of December 2019 and considerable efforts to reduce transmission will be required to control outbreaks if similar dynamics apply elsewhere.
Journal ArticleDOI
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Daniel Wrapp,Nianshuang Wang,Kizzmekia S. Corbett,Jory A. Goldsmith,Ching-Lin Hsieh,Olubukola M. Abiona,Barney S. Graham,Jason S. McLellan +7 more
TL;DR: The authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor, and test several published SARS-CoV RBD-specific monoclonal antibodies found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs.
Journal ArticleDOI
Re-epithelialization and immune cell behaviour in an ex vivo human skin model.
TL;DR: A novel wound model based on application of negative pressure and its effects for epidermal regeneration and immune cell behaviour is presented, which recapitulates the main features of epithelial wound regeneration, and can be applied for testing wound healing therapies and investigating underlying mechanisms.
Related Papers (5)
A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
Tingting Li,Hongmin Cai,Hebang Yao,Bingjie Zhou,Ning Zhang,Martje Fentener van Vlissingen,Thijs Kuiken,Wenyu Han,Corine H. GeurtsvanKessel,Yuhuan Gong,Yapei Zhao,Quan Shen,Wenming Qin,Xiao-Xu Tian,Chao Peng,Yanling Lai,Yanxing Wang,Cedric A. J. Hutter,Shu-Ming Kuo,Juan Bao,Caixuan Liu,Yifan Wang,Audrey Richard,Hervé Raoul,Jiaming Lan,Markus A. Seeger,Yao Cong,Barry Rockx,Gary Wong,Gary Wong,Yuhai Bi,Dimitri Lavillette,Dimitri Lavillette,Dianfan Li +33 more